Neuroimmune mechanisms of lipocalin 2 in mediating chronic pain and itch

Published on March 4, 2026

Sheng Li Xue Bao. 2026 Feb 25;78(1):57-70.

ABSTRACT

Lipocalin 2 (LCN2), a member of the lipocalin superfamily, is expressed and secreted by various cells and functions as a transport protein for lipophilic small molecules such as steroids, lipopolysaccharides, iron and fatty acids. LCN2 plays a significant role in pain modulation, particularly in the development and maintenance of inflammatory pain and chronic neuropathic pain. Its mechanisms involve the regulation of neuroinflammation and the modulation of neuron-glia interactions. LCN2 also demonstrates notable effects in itch regulation, where it binds to specific receptors and activates downstream signaling pathways, contributing to the induction and persistence of chronic itch. This review summarizes recent advances in the fundamental research on LCN2 in the regulation of chronic pain and itch, and discusses its potential value as a therapeutic target, aiming to provide a theoretical foundation for developing novel treatment strategies.

PMID:41777130

Continue reading on website
Other news

New insights into the pain of knee osteoarthritis: the characteristics of deep pain and abnormal central processing

March 4, 2026
Sheng Li Xue Bao. 2026 Feb 25;78(1):47-56.ABSTRACTKnee osteoarthritis (KOA) represents one of the most common causes of chronic pain. The high prevalence and disability rates of KOA impose a severe burden on both individuals and society. In contrast to cutaneous pain, KOA-induced joint pain is characterized as a deep tissue pain that potentially involves distinct subgroups of peripheral sensory ne

Research progress on neurobiological mechanisms of chronic postoperative pain

March 4, 2026
Sheng Li Xue Bao. 2026 Feb 25;78(1):83-100.ABSTRACTPostoperative pain is a common complication caused by surgical trauma. Epidemiological studies indicate that the incidence of moderate to severe acute postoperative pain ranges from 41% to 85%, with approximately 10% to 50% of patients potentially progressing to chronic pain. This progression not only significantly impairs patients' quality of lif